Prezelin-Reydit, Mathilde
Combe, Christian
Fouque, Denis
Frimat, Luc
Jacquelinet, Christian
Laville, Maurice
Massy, Ziad A.
Lange, Céline
Ayav, Carole
Pecoits-Filho, Roberto
Liabeuf, Sophie
Stengel, Bénédicte
Harambat, Jérôme
Leffondré, Karen
de Pinho, Natalia Alencar
Herpe, Yves-Edouard
Pascal, Christophe
Schanstra, Joost
Lambert, Oriane
Metzger, Marie
Speyer, Elodie
,
Article History
Received: 1 February 2022
Accepted: 3 March 2023
First Online: 9 March 2023
Competing interests
: CKD-REIN is supported by a public–private partnership with funding from seven pharmaceutical companies as listed above. The partners did not participate in this work nor in the writing of the manuscript. CKD-REIN is funded by the ‘Agence Nationale de la Recherche’ through the 2010 ‘Cohortes-Investissements d’Avenir’ programme and by the 2010 national ‘Programme Hospitalier de Recherche Clinique’. CKD-REIN is also supported through a public–private partnership with Amgen, Baxter, Fresenius Medical Care, GlaxoSmithKline (GSK), Merck Sharp & Dohme-Chibret (MSD France) since 2012, Lilly France since 2013, Otsuka Pharmaceutical since 2015 and Sanofi-Genzyme from 2012 to 2015. Inserm Transfert set up and has managed this partnership since 2011. The remaining authors do not have any conflict of interest to declare.